GRAIL Announces Inducement Grants to Expand Workforce
GRAIL, Inc. (Nasdaq: GRAL), a pioneering healthcare company, has made significant strides in its mission to detect cancer early when it is most treatable. Recently, GRAIL announced the granting of equity awards in the form of restricted stock units (RSUs), covering a total of 47,150 shares of its common stock. This move is aimed at 27 newly hired non-executive employees, serving as an essential inducement for their acceptance of positions at GRAIL.
Details of the Inducement Grants
The employment inducement awards are part of GRAIL's Inducement Equity Incentive Plan, which complies with Nasdaq Listing Rule 5635(c)(4). These grants are particularly designed for those who have not previously been part of GRAIL’s workforce, providing them a compelling incentive to join the organization. The structure of these grants reflects GRAIL's commitment to building a talented team that can contribute to its pivotal mission.
Vesting Schedule of RSUs
The RSUs awarded to the new hires are set to vest over approximately four years. Notably, 25% of the total award is slated to vest on the first anniversary of the grant's effective date, with subsequent portions vesting on each anniversary thereafter. This structure ensures that the employees remain aligned with GRAIL's long-term objectives and contribute actively throughout their employment period.
About GRAIL
GRAIL is at the forefront of cancer detection innovation. Its mission revolves around the early identification of cancer, which significantly enhances the chances of successful treatment. The company’s advanced methodologies utilize next-generation sequencing, large-scale clinical research, and cutting-edge machine learning technologies. These innovations help GRAIL identify several aggressive cancer types much earlier, facilitating a multidisciplinary approach to cancer care.
Innovative Technologies in Cancer Detection
By leveraging a targeted methylation-based platform, GRAIL supports various aspects of cancer care, from early detection in symptomatic patients to treatment monitoring and biomarker subtyping. This groundbreaking technology not only aids in early detection but also plays a crucial role in the continuum of care, including risk stratification and minimal residual disease detection.
Global Presence of GRAIL
Headquartered in California, GRAIL has expanded its reach beyond state lines, with additional locations in Washington, D.C., North Carolina, and the United Kingdom. This global footprint underscores GRAIL’s ambition to address the worldwide burden of cancer effectively.
Frequently Asked Questions
1. What is the main goal of GRAIL?
GRAIL aims to detect cancer at an early stage when it is most treatable, using innovative technologies to improve outcomes for patients.
2. What type of awards did GRAIL offer to new employees?
GRAIL granted restricted stock units (RSUs) as inducement to attract new non-executive employees.
3. How many shares are included in the inducement grants?
The inducement grants encompass a total of 47,150 shares of GRAIL’s common stock.
4. How do the RSUs vest?
The RSUs vest over four years, with 25% vesting on the first anniversary and subsequently on each yearly anniversary thereafter.
5. Where is GRAIL headquartered?
GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom.
